Cara Community Biotechs: Fate

Fate Therapeutics (NASDAQ: FATE) reviewed 10-14-2020

Market Cap: $4.1 Billion (USD)                   Share Price: $46.96 (USD)

Shares outstanding: 86,802,162

Cash & cash equivalents: $433 Million (USD) at 30 Jun 2020

Debt:  None stated on the balance sheet

Insiders: 2%        Institutional: 221 holders own 96% of the float

Website: fatetherapeutics.com

Investor Presentations: https://ir.fatetherapeutics.com/

CEO: Scott Wolchko                        HQs: San Diego, CA USA

The company is developing cellular immunotherapy technologies for cancer and immune disorders

The company has about 14 iPSC-derived cell products in the pipeline in various Pre-clinical stages

Revenues improved in 2019 to $10.68M (USD) from $4.74M (USD) in 2018

The company has been operating at a loss for consecutive years

Loss of $0.79 (USD) per share in the six months to 30 Jun 2020. Lost $0.66 (USD) per share in the same period of 2019

Has collaborations with Janssen Biotech and Ono Pharmaceutical Co., the Masonic Cancer Center in Minneapolis, Minnesota, the Memorial Sloan-Kettering Cancer Center, and Oslo University

Bottom Line:

  • Uses pluripotent stem cell line to discover immunotherapies for cancer and immune disorders, which if their phase 2 clinical trial is successful, we believe the company is a buy-out candidate

Like to give your opinion? Join our Community Discussion